RxMP Therapeutics, INC
RxMP Therapeutics is dedicated to developing innovative therapies aimed at preventing and treating hemorrhage and excessive bleeding. The company focuses on creating novel hemostatic agents that can effectively stop bleeding while minimizing the risk of unwanted clotting elsewhere in the body. Their lead product, RMP-402, has significant market potential and is backed by substantial funding to support its development.
What We Do
RMP-402
RMP-402 is produced via the high-pressure extrusion of multiple units of human packed red blood cells. It has demonstrated efficacy in multiple animal models of bleeding and hemorrhage, enhancing both platelet function and coagulation without causing off-target clotting. RMP-402 meets the criteria of a universal hemostatic agent.
Application Area
Regenerative Medicine
Biologics
Key People
Rifat Pamukcu, M.D.
President and CEO, Director
Bob Baltera
Director
Wenche Jy, Ph.D.
CSO, Director
Sue Van
Director
Michael Davis, M.D. FACS
Consultant
Yeon Ahn, M.D.
Prof. of Medicine
Sam Schulman, MD FRCPC(C)
Director of Clinical Thromboembolism Program
Barth Green, MD FACS
Prof. and Fmr Chairman of Dept. of Neurological Surgery
Jerrold Levy, MD FAHA FCCM
Co-Director, Cardiothoracic Surgical Intensive Care Unit
News & Updates
RxMP Therapeutics Provides Documents for Latest Raise
RxMP Therapeutics has provided documents related to their latest fundraising efforts.
Dr. Rif Pamukcu CEO and Dr. Mike Davis provide shareholders an update on the current raise and outlook for 2024.
Rif Pamukcu and Bob Baltera provide viewers with a current update on the company's business initiatives.